Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
14 /100
LOW RISK
Score updated Jul 28, 2026

TRVI — Trevi Therapeutics, Inc. Dilution Risk Tracker

Track TRVI dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track TRVI — Get alerts when the score changes →

As of July 28, 2026, Trevi Therapeutics, Inc. (TRVI) has a DilutionWatch DilutionScore of 14/100, rated LOW dilution risk. Trevi Therapeutics, Inc. has a market capitalization of $2.01B, 141.98M shares outstanding, 201 institutional holders tracked. Key dilution vectors include approximately 42 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
32
💰 Cash Runway
0
📊 Float Risk
7
⚠️ Warrant Exposure
15
🔄Convertible Debt

Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for TRVI.
🔔 Track TRVI — Get forecast alerts →

Market Data

Market Cap$2.01B
Shares Outstanding141.98M
Float117.83M
Cash$171.78M
DebtN/A
Short InterestN/A

Institutional Holdings

QoQ: ↑ 16.0% shares (2026Q1 vs prior)
201 institutional holders · 154.93M shares
#1 NEA Management Company, LLC 13.22M shares
#2 BlackRock, Inc. 10.24M shares
#3 Vivo Capital, LLC 10.19M shares
+ 17 more holders Sign up free to view →

Short Interest

Short Interest12.65M
Days to Cover4.8
% of Float10.7%
FINRA data as of Jul 15, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31
xbrl XBRL CONVERTIBLE 2019-12-31
4 INSIDER TRANSACTION 2026-02-20
4 INSIDER TRANSACTION 2026-02-20
4 INSIDER TRANSACTION 2026-02-20
Full SEC filing analysis available with free account

Recent News

No recent news

What This Means for TRVI Shareholders

Trevi Therapeutics, Inc. (TRVI) has a DilutionScore of 14/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 28, 2026.

DilutionWatch's EDGAR monitoring for TRVI shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for TRVI in real-time, scanning EDGAR every 60 seconds. The DilutionWatch shows real-time score changes for TRVI alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Understanding TRVI's Dilution Risk Factors

Primary Risk Drivers

The most significant dilution risks for Trevi Therapeutics are linked to its Offering Ability and Cash Runway scores. Offering Ability is currently at a moderate level, indicating the company has the capacity to raise capital through equity offerings, which could dilute existing shareholders. The Cash Runway score of zero means the company is in a strong financial position with no immediate cash concerns, but it also implies that the company may be more inclined to issue new shares to fund operations or growth initiatives. These two factors together create a potential for dilution if the company chooses to raise funds through equity rather than debt or internal cash generation.

Factors Currently Not a Concern

Float Risk, Warrant Exposure, and Convertible Note Risk are all low in the current assessment, suggesting that existing shareholders face minimal risk from these sources. Float Risk is at an extremely low level, indicating limited shares available for trading, which reduces dilution risk from market liquidity concerns. Warrant Exposure and Convertible Note Risk are similarly low, showing that the company has few outstanding warrants or convertible debt that could convert into equity. Any change in capital structure, such as issuing new warrants or entering into convertible note agreements, would elevate these scores and increase dilution exposure.

SEC Filings to Watch

Several SEC filings are critical for monitoring TRVI’s potential dilution risk. S-3 registrations signal the company's intent to register securities for future issuance, which may include equity offerings. 424B5 filings typically relate to prospectus supplements and often indicate upcoming offerings. Item 1.01 of an 8-K report highlights material events such as new equity issuances or changes in capital structure that could affect share count. Quarterly reports (10-Q) are also important, as they reveal changes in capitalization, including new share issuance or debt-to-equity conversions that may impact existing shareholders.

How Dilution Happens

Dilution occurs when a company issues additional shares, reducing the ownership percentage of existing shareholders. For TRVI, if the company raises funds through equity offerings, the Offering Ability score increases the likelihood of such issuance. If the company needs to issue new shares to fund operations or growth, the Cash Runway score being zero indicates no immediate financial pressure but also suggests a readiness to issue more stock if needed. As these new shares are issued, existing shareholders’ stakes decrease proportionally, leading to dilution.

What Would Make This Worse

A significant deterioration in TRVI’s risk profile would occur if the company enters into convertible note agreements or issues warrants with low strike prices, increasing Warrant Exposure and Convertible Note Risk. Additionally, a shift from a zero Cash Runway score to a higher one would signal financial strain, potentially forcing the company to issue more equity to stay afloat. Any major capital raise through an S-3 registration or a large 424B5 filing could also increase Offering Ability significantly and expose shareholders to greater dilution risk.

Key Insight

While TRVI’s current dilution profile is low, the potential for future dilution exists if the company chooses to issue new equity or enters into convertible agreements.

How to Monitor TRVI for Dilution Risk

What This Risk Level Means

For a mid-cap operating company like Trevi Therapeutics, a moderate dilution risk profile signals that while the company is not currently in immediate danger of excessive share issuance, there are underlying factors that could lead to dilution pressures. The company's size and stage of development make it more susceptible to capital-raising activities, especially as it may need funds for research, clinical trials, or operational scaling. With a score indicating potential risk, the company is at a point where strategic decisions around equity issuance could significantly impact shareholder value. A low dilution score does not mean no risk — rather, it suggests that while the company is currently managing its capital structure prudently, vigilance is required.

What Typically Happens Next

Companies at this profile often proceed with capital-raising activities such as shelf registrations or ATM programs to secure funds for growth initiatives. These mechanisms allow for flexible funding without the need for lengthy regulatory processes. For mid-cap companies, warrant exercises and rights offerings are also common strategies to raise capital while offering investors upside potential. The timing of these events can be unpredictable but often aligns with key milestones in product development or market expansion phases. Monitoring these activities is essential to assess if dilution pressures are escalating.

Monitoring Playbook

To track TRVI effectively, use DilutionWatch to set up alerts for any changes in DilutionScore or Offering Ability. Check the company’s filings weekly and set thresholds for score increases above 20 points as early warnings. Monitor Shelf & ATM Monitor for any new registration announcements or active programs. When thresholds are hit, review SEC documents such as Form S-1, S-3, or prospectus amendments for details on issuance plans and investor rights.

Early Warning Signals

Three key signals to watch for include: 1) An increase in Offering Ability score above 40/100, indicating a higher risk of equity issuance; 2) Filing for new shelf registrations or ATM programs in SEC documents; and 3) A sudden spike in warrant or option activity in the company’s filings. These changes often precede actual dilution events and should trigger immediate review.

What a Positive Resolution Looks Like

A positive shift in TRVI’s profile would occur if the company completes a capital raise that reduces reliance on future equity issuance, or if warrant exercises are fully accounted for and no longer pose a risk. Another resolution path is when the Offering Ability factor drops below 30/100 due to reduced plans for new share issuance. These changes would indicate that dilution pressures have been mitigated, improving the company’s financial stability and shareholder position.

Watch For

Any sudden increase in Offering Ability or filing of new equity programs, as these are strong indicators of potential dilution risk.

Full SEC filing analysis available with free account  →
Track TRVI Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking TRVI — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for TRVI
TRVI FDA Catalyst Timeline & Biotech Grade — BiotechSignsTRVI Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.